December 04, 2014
NASHVILLE, TN., Dec. 4, 2014 – Sarah Cannon announced today that the American Society of Hematology (ASH) has selected 51 abstracts authored by members of the Sarah Cannon Blood Cancer Network to be presented at the 2014 ASH Meeting and Exposition. Hosted in San Francisco from Dec. 6 - 9, the meeting brings together more than 20,000 hematologists and other oncology professionals from a broad range of specialties to discuss the latest breakthroughs in blood cancer research and treatment.
“Sarah Cannon’s representation at ASH continues to grow, demonstrating our organization’s expertise and collaborative approach to advancing novel therapies for blood cancers,” said Howard A. “Skip” Burris III, MD, President, Clinical Operations for Sarah Cannon. “As a leading cancer network of excellence, we are committed to weaving together personalized treatment, innovative science and compassionate care.”
Members of the Sarah Cannon Blood Cancer Network comprise physician leaders from six FACT accredited blood cancer programs, including 7 principal investigators from Sarah Cannon Research Institute (SCRI). Of the 51 accepted abstracts, 39 trials are being conducted by SCRI, which highlight 10 oral sessions and 29 posters representing in-progress trials.
In addition to the poster and oral sessions, two of SCRI’s principal investigators will present in Friday Satellite Symposia sessions. Jesus G. Berdeja, MD, Director of Myeloma Research at SCRI, will present the latest research on personalizing multiple myeloma treatment for the maximum benefit of the patient. Ian W. Flinn, MD, PhD, Director of Hematologic Malignancies Research at SCRI, will discuss evolving therapies for indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia, including how to apply the latest developments to clinical practice.
“Sarah Cannon is committed to advancing cancer treatment through personalized approaches to care that combine known best practices with an individualized, patient-focused plan,” said Berdeja. “I am looking forward to sharing some of our latest ideas and giving colleagues a chance to apply an individualized, patient-centered approach to the management of multiple myeloma through an iPad-based learning opportunity during our symposium.”
About The Sarah Cannon Blood Cancer Network
The Sarah Cannon Blood Cancer Network is one of the largest providers of blood cancer care including blood and marrow transplantation (BMT) across the United States and United Kingdom. Its network conducts over 900 transplants annually and has treated more than 10,000 patients since the inception of our first program. Through its commitment to the highest level of quality standards, infrastructure, training and research, the Sarah Cannon Blood Cancer Network provides an unparalleled experience for patients seeking treatment. For more information about the Blood Cancer Network and Sarah Cannon’s full suite of cancer services, please visit: sarahcannon.com.
About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies for patients. It is one of the world’s leading clinical research programs, conducting community-based clinical trials in oncology and cardiology through affiliations with a network of more than 1,000 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory, and other research support services for drug development and industry sponsors and strategic investigator sites. For more information, please visit sarahcannon.com.